icrn phw energy cse dte gobar times rwh csestore iep aaeti
Patently Absurd

Finally, a US revolt on drug price

Issue Date: Jul 15, 2015
Gilead sciences became the poster boy for high drug prices when it launched Sovaldi to treat hepatitis C, a course of treatment that cost US $84,000, or US $1,000 a pill. That shocked the world. There was outrage even in the developed world which has always defended the high prices charged by innovator companies as the cost of encouraging R&D and bringing new drugs to the market.

WTO gives India a clean chit

Issue Date: Jun 30, 2015

IPR course in school? It's silly

Issue Date: Jun 15, 2015

Ignore US bullying on IPRs

Issue Date: May 31, 2015
It's that time of the year when the US hectors and bullies an assorted collection of countries that have failed to meet its standards of intellectual property rights (IPRs) protection. The standards that it demands from its trading partners are way beyond what the World Trade Organization (WTO) rules require but for well over two decades the US Trade Representative (USTR) has used its annual Special 301 Report to keep “defaulting” countries in line through a naming and shaming exercise.

Doing very nicely without IPRs

Issue Date: May 15, 2015

Push for open source software

Issue Date: Apr 30, 2015
It has taken the government of India a decade and more to grasp a basic truth—that open source software (OSS) is the way to go. March-end, the Information Technology (IT) ministry unveiled, finally, a policy for adopting OSS as the preferred option in all e-governance systems implemented by various government organisations. The policy, which makes it mandatory to adopt OSS, is intended to lower costs and ensure strategic control of these systems. It says the aim is to ensure “efficiency, transparency and reliability of such services at affordable costs”. Sigh.

Why do we need patents?

Issue Date: Apr 15, 2015
As we enjoy great advantages from the inventions of others, we should be glad of an opportunity to serve others by any invention of ours; and this we should do freely and generously.” So wrote Benjamin Franklin, America’s founding father and man of many parts, in his autobiography explaining why he had refused a patent for a more efficient open stove he had invented in 1742.

Pushing limits of drug access

Issue Date: Mar 31, 2015
Among the goods that come within the ambit of intellectual property rights (IPRs), none is more contentious than pharmaceuticals, specially those medicines that are categorised as life-saving. The high pricing of such drugs, ostensibly on account of the huge cost of discovery and research and development, is the bone of contention.

Bitter ABS medicine for AYUSH

Issue Date: Mar 15, 2015
What's good for biodiversity is not always good for business—or so it appears. The long overdue guidelines on access and benefit sharing (ABS) of biological resources notified by the Union Ministry of Environment, Forest and Climate Change (MoEF&CC) in November 2014 is proving to be bitter physic for the makers of AYUSH or traditional medicines who fear their healthy profits will decline.

The innovation WHO needs

Issue Date: Feb 28, 2015
Six years ago, the World Health Organization (WHO) adopted a Strategy and Plan of Action on Public Health, Innovation and Intellectual Property (IP), or GSPA as it is known, to “foster innovation and improve access for people in developing countries”. At its executive board meeting that ended on February 3, the board recommended extension of GSPA until 2022.
CSE WEBNET
Follow us ON
Follow grebbo on Twitter    Google Plus  DTE Youtube  rss